Nymox Pharmaceuticals Corporation (NYMX) Company Profile - CorporateInformation.com

Company Search:

Advanced Search

Wright Investors Service Perspectives


	The Wright Reports site is no longer hosted or operated by Manta. Please review the following: 1. You have been redirected to CorporateInformation.com where you can view Snapshot reports or purchase Wright reports or subscriptions of your choosing. 2. If you were previously linking to Wright Reports please change your links to www.corporateinformation.com 3. If you are a paid subscriber with an active subscription please continue on to the member site: http://member.corporateinformation.com/home.asp 4. For additional information related to CorporateInformation.com please contact help@corporateinformation.com, Contact phone nr to be provided later)

Nymox Pharmaceuticals Corporation Company Snapshot

Business Description:

Nymox Pharmaceuticals Corporation operates in the Diagnostic substances sector. Nymox Pharmaceutical Corporation (Nymox) is a biopharmaceutical company. The Company has research and development (R&D) pipeline of products in development for the treatment of such conditions and diseases as enlarged prostate (benign prostatic hyperplasia (BPH)), Alzheimer's disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. Nymox also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. Nymox has two subsidiaries: Nymox Corporation and Serex, Inc. Nymox has developed a drug screening system, based on the research that led to its AlzheimAlert test, to identify other drug candidates for the treatment of Alzheimer's disease. The Company is in the preclinical stage of developing therapeutic products for oncological indications based on technology licensed from the Massachusetts General Hospital. In our complete report available for purchase the company is compared to: Medmira Inc., Oncothyreon Incorporation and Alda Pharmaceuticals Corp..

Nymox Pharmaceuticals Corporation

Stock Performance Chart for Nymox Pharmaceuticals Corporation

Stock Data:

Recent Stock Performance:

Current Price (2/3/2012): 8.82
(Figures in Canadian Dollars)

1 Week	8.8%		13 Weeks	6.6%

4 Weeks	-2.6%		52 Weeks	21.5%

Nymox Pharmaceuticals Corporation Key Data:

	Ticker:	NYMX	Country:	CANADA

	Exchanges:	NAS	Major Industry:	Drugs, Cosmetics & Health Care

			Sub Industry:	Ethical Drug Manufacturers

	2010 Sales	716,017 (Year Ending Jan 2011).	Employees:	22

	Currency:	Canadian Dollars	Market Cap:	291,000,924

	Fiscal Yr Ends:	December	Shares Outstanding:	32,993,302

	Share Type:	Common	Closely Held Shares:	13,181,495

Feedback | Terms and Conditions | Privacy Policy | Site Index

CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.